Venous Leg Ulcers (Crural ulcer) - Pipeline Review, H2 2014

Published: Jul, 2014 | Pages: 74 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Venous Leg Ulcers (Crural ulcer) - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Venous Leg Ulcers (Crural ulcer) - Pipeline Review, H2 2014', provides an overview of the Venous Leg Ulcers (Crural ulcer)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Venous Leg Ulcers (Crural ulcer), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Venous Leg Ulcers (Crural ulcer) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Venous Leg Ulcers (Crural ulcer)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Venous Leg Ulcers (Crural ulcer) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Venous Leg Ulcers (Crural ulcer) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Venous Leg Ulcers (Crural ulcer) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Venous Leg Ulcers (Crural ulcer)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Venous Leg Ulcers (Crural ulcer) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Venous Leg Ulcers (Crural ulcer) Overview 8
Therapeutics Development 9
Pipeline Products for Venous Leg Ulcers (Crural ulcer) - Overview 9
Pipeline Products for Venous Leg Ulcers (Crural ulcer) - Comparative Analysis 10
Venous Leg Ulcers (Crural ulcer) - Therapeutics under Development by Companies 11
Venous Leg Ulcers (Crural ulcer) - Therapeutics under Investigation by Universities/Institutes 13
Venous Leg Ulcers (Crural ulcer) - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Venous Leg Ulcers (Crural ulcer) - Products under Development by Companies 17
Venous Leg Ulcers (Crural ulcer) - Products under Investigation by Universities/Institutes 18
Venous Leg Ulcers (Crural ulcer) - Companies Involved in Therapeutics Development 19
Smith & Nephew Plc 19
CardioVascular BioTherapeutics, Inc. 20
Stratatech Corporation 21
RegeneRx Biopharmaceuticals, Inc. 22
CytoTools AG 23
FirstString Research, Inc. 24
CoDa Therapeutics, Inc. 25
Adocia 26
Intralytix, Inc. 27
MacroCure 28
Pergamum AB 29
Venous Leg Ulcers (Crural ulcer) - Therapeutics Assessment 30
Assessment by Monotherapy Products 30
Assessment by Target 31
Assessment by Mechanism of Action 33
Assessment by Route of Administration 35
Assessment by Molecule Type 37
Drug Profiles 39
HP-802247 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
CureXcell - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Granexin - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
CVBT-141B - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
RGN-137 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
DermaPro CL-05 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
CODA-001 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
LL-37 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Stem Cell Therapy for Venous Leg Ulcers - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
WPP-201 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Biochaperone PDGF-BB - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Cathelicidin - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Venous Leg Ulcers (Crural ulcer) - Recent Pipeline Updates 57
Venous Leg Ulcers (Crural ulcer) - Dormant Projects 64
Venous Leg Ulcers (Crural ulcer) - Discontinued Products 65
Venous Leg Ulcers (Crural ulcer) - Product Development Milestones 66
Featured News & Press Releases 66
May 05, 2014: Subsidiary DermaTools Biotech starts European clinical phase II/III trial with wound healing medication DermaPro for ulcus cruris indication 66
Oct 10, 2013: Pergamum announces final data from Phase I/II study of LL-37 in patients with chronic leg ulcers 66
Apr 19, 2013: Pergamum Reaches Last-Patient-Last-Visit In Phase I/II Trial Of LL-37 For Treatment Of Venous Leg Ulcers 67
Jan 09, 2013: CoDa Therapeutics Announces Positive Results From Phase IIb Study Of Nexagon In Chronic Venous Leg Ulcers 68
Sep 11, 2012: Healthpoint Biotherapeutics Initiates Phase III Study Of Investigational Cell-Based Therapy For Venous Leg Ulcers 68
Sep 11, 2012: Pergamum Announces Dosing Of First Patient In Phase I/II trial Of LL-37 For Hard-to-heal Wounds 69
Aug 02, 2012: Healthpoint Biotherapeutics Announces Publication Of Phase IIb Study Results Of Investigational Cell-Based Therapy In Lancet 69
Jul 25, 2012: Healthpoint Biotherapeutics Announces Phase II Trial Results Of HP802-247 For Venous Leg Ulcers 70
Aug 04, 2011: Healthpoint Biotherapeutics Announces Positive Results From Phase IIb Trial Of HP802-247 In Venous Leg Ulcers 71
Mar 26, 2009: RegeneRx Reports Phase II Venous Stasis Trial Results 72
Appendix 73
Methodology 73
Coverage 73
Secondary Research 73
Primary Research 73
Expert Panel Validation 73
Contact Us 74
Disclaimer 74

List of Tables
Number of Products under Development for Venous Leg Ulcers (Crural ulcer), H2 2014 9
Number of Products under Development for Venous Leg Ulcers (Crural ulcer) - Comparative Analysis, H2 2014 10
Number of Products under Development by Companies, H2 2014 12
Number of Products under Investigation by Universities/Institutes, H2 2014 13
Comparative Analysis by Late Stage Development, H2 2014 14
Comparative Analysis by Clinical Stage Development, H2 2014 15
Comparative Analysis by Early Stage Development, H2 2014 16
Products under Development by Companies, H2 2014 17
Products under Investigation by Universities/Institutes, H2 2014 18
Venous Leg Ulcers (Crural ulcer) - Pipeline by Smith & Nephew Plc, H2 2014 19
Venous Leg Ulcers (Crural ulcer) - Pipeline by CardioVascular BioTherapeutics, Inc., H2 2014 20
Venous Leg Ulcers (Crural ulcer) - Pipeline by Stratatech Corporation, H2 2014 21
Venous Leg Ulcers (Crural ulcer) - Pipeline by RegeneRx Biopharmaceuticals, Inc., H2 2014 22
Venous Leg Ulcers (Crural ulcer) - Pipeline by CytoTools AG, H2 2014 23
Venous Leg Ulcers (Crural ulcer) - Pipeline by FirstString Research, Inc., H2 2014 24
Venous Leg Ulcers (Crural ulcer) - Pipeline by CoDa Therapeutics, Inc., H2 2014 25
Venous Leg Ulcers (Crural ulcer) - Pipeline by Adocia, H2 2014 26
Venous Leg Ulcers (Crural ulcer) - Pipeline by Intralytix, Inc., H2 2014 27
Venous Leg Ulcers (Crural ulcer) - Pipeline by MacroCure, H2 2014 28
Venous Leg Ulcers (Crural ulcer) - Pipeline by Pergamum AB, H2 2014 29
Assessment by Monotherapy Products, H2 2014 30
Number of Products by Stage and Target, H2 2014 32
Number of Products by Stage and Mechanism of Action, H2 2014 34
Number of Products by Stage and Route of Administration, H2 2014 36
Number of Products by Stage and Molecule Type, H2 2014 38
Venous Leg Ulcers (Crural ulcer) Therapeutics - Recent Pipeline Updates, H2 2014 57
Venous Leg Ulcers (Crural ulcer) - Dormant Projects, H2 2014 64
Venous Leg Ulcers (Crural ulcer) - Discontinued Products, H2 2014 65